Lyell Immunopharma (LYEL) Competitors $11.02 -0.79 (-6.69%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.08 +0.05 (+0.50%) As of 08/1/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LYEL vs. UPB, BCYC, KROS, KURA, TBPH, ARVN, SEPN, SAGE, TYRA, and TSHAShould you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include Upstream Bio (UPB), Bicycle Therapeutics (BCYC), Keros Therapeutics (KROS), Kura Oncology (KURA), Theravance Biopharma (TBPH), Arvinas (ARVN), Septerna (SEPN), Sage Therapeutics (SAGE), Tyra Biosciences (TYRA), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. Lyell Immunopharma vs. Its Competitors Upstream Bio Bicycle Therapeutics Keros Therapeutics Kura Oncology Theravance Biopharma Arvinas Septerna Sage Therapeutics Tyra Biosciences Taysha Gene Therapies Upstream Bio (NASDAQ:UPB) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability. Do analysts rate UPB or LYEL? Upstream Bio presently has a consensus target price of $56.50, indicating a potential upside of 263.58%. Lyell Immunopharma has a consensus target price of $15.00, indicating a potential upside of 36.12%. Given Upstream Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Upstream Bio is more favorable than Lyell Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Is UPB or LYEL more profitable? Upstream Bio has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -514,649.22%. Upstream Bio's return on equity of 0.00% beat Lyell Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Upstream BioN/A N/A N/A Lyell Immunopharma -514,649.22%-73.66%-60.99% Do institutionals and insiders believe in UPB or LYEL? 66.1% of Lyell Immunopharma shares are held by institutional investors. 13.6% of Upstream Bio shares are held by company insiders. Comparatively, 22.3% of Lyell Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better earnings and valuation, UPB or LYEL? Upstream Bio has higher revenue and earnings than Lyell Immunopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpstream Bio$2.30M364.09-$62.81MN/AN/ALyell Immunopharma$60K2,720.10-$342.99M-$25.00-0.44 Does the media prefer UPB or LYEL? In the previous week, Upstream Bio had 2 more articles in the media than Lyell Immunopharma. MarketBeat recorded 4 mentions for Upstream Bio and 2 mentions for Lyell Immunopharma. Upstream Bio's average media sentiment score of 0.32 beat Lyell Immunopharma's score of -0.66 indicating that Upstream Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative SummaryUpstream Bio beats Lyell Immunopharma on 10 of the 13 factors compared between the two stocks. Get Lyell Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LYEL vs. The Competition Export to ExcelMetricLyell ImmunopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$174.88M$2.50B$5.48B$9.54BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-0.448.9728.8623.83Price / Sales2,720.10436.67371.7266.14Price / CashN/A157.7635.4557.96Price / Book0.424.838.275.54Net Income-$342.99M$31.62M$3.25B$259.28M7 Day Performance-11.27%-5.28%-3.73%-4.68%1 Month Performance16.86%4.38%4.29%4.36%1 Year Performance-63.02%-2.49%25.87%17.89% Lyell Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LYELLyell Immunopharma2.9656 of 5 stars$11.02-6.7%$15.00+36.1%-63.3%$174.88M$60K-0.44270Upcoming EarningsGap DownUPBUpstream Bio2.0621 of 5 stars$10.74+0.9%$56.50+426.3%N/A$577.44M$2.37M0.0038Upcoming EarningsGap DownBCYCBicycle Therapeutics3.4282 of 5 stars$8.40+1.1%$24.22+188.4%-67.2%$573.42M$25.72M-2.64240Upcoming EarningsGap DownKROSKeros Therapeutics2.5921 of 5 stars$13.92+0.9%$30.56+119.6%-71.6%$566.65M$3.55M-77.50100News CoveragePositive NewsUpcoming EarningsKURAKura Oncology3.3434 of 5 stars$6.54+1.0%$24.50+274.8%-70.2%$565.77M$67.99M-3.11130News CoverageUpcoming EarningsTBPHTheravance Biopharma1.814 of 5 stars$11.27-0.7%$16.60+47.3%+8.7%$563.51M$65.27M-9.55110Upcoming EarningsARVNArvinas3.4814 of 5 stars$7.62+1.3%$20.29+166.4%-72.3%$555.82M$263.40M-11.54420News CoverageUpcoming EarningsSEPNSepterna1.3689 of 5 stars$12.32+0.0%$26.75+117.2%N/A$549.29M$1.08M0.00N/ASAGESage Therapeutics3.7214 of 5 stars$8.77-2.3%$8.23-6.1%-11.0%$548.87M$47.40M-1.51690News CoverageEarnings ReportAnalyst UpgradeHigh Trading VolumeTYRATyra Biosciences1.6684 of 5 stars$10.26-3.3%$30.83+200.6%-51.8%$546.83MN/A-6.3220News CoverageUpcoming EarningsShort Interest ↑TSHATaysha Gene Therapies2.9443 of 5 stars$2.52-0.6%$8.17+224.7%+21.8%$539.87M$8.33M-7.40180News CoverageShort Interest ↑ Related Companies and Tools Related Companies UPB Alternatives BCYC Alternatives KROS Alternatives KURA Alternatives TBPH Alternatives ARVN Alternatives SEPN Alternatives SAGE Alternatives TYRA Alternatives TSHA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LYEL) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
